Here's Why Baxter International (BAX) is a Strong Value Stock

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through various research services [1] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [2] - Each stock is assigned a rating from A to F, with A indicating the highest potential for outperformance [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [2] Growth Score - The Growth Style Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [3] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes, aiding investors in timing their purchases of high-momentum stocks [3] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores to identify stocks with the best overall potential [4] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks yielding an average annual return of +25.41% since 1988 [5] - There are over 800 stocks rated 1 or 2, which can be overwhelming for investors [5] Stock to Watch: Baxter International (BAX) - Baxter International Inc. is a global medical technology company with a presence in over 100 countries, focusing on products and digital health solutions for healthcare organizations [7] - BAX currently holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of A, indicating strong potential [7] - The company has a Value Style Score of A, supported by a forward P/E ratio of 11.4, making it attractive to value investors [7] - Analysts have recently revised BAX's earnings estimate upwards, with the Zacks Consensus Estimate increasing by $0.02 to $2.91 per share for fiscal 2024 [7]